CPI-169
10mM in DMSO
- Product Code: 158026
CAS:
1450655-76-1
| Molecular Weight: | 528.66 g./mol | Molecular Formula: | C₂₇H₃₆N₄O₅S |
|---|---|---|---|
| EC Number: | MDL Number: | ||
| Melting Point: | Boiling Point: | ||
| Density: | Storage Condition: | -20°C |
Product Description:
CPI-169 is primarily used in research settings as a potent and selective inhibitor of the menin-MLL (mixed lineage leukemia) protein-protein interaction. This interaction plays a critical role in the development and progression of certain types of leukemia, particularly MLL-rearranged (MLL-r) leukemias. By disrupting this interaction, CPI-169 has shown promise in suppressing the growth of leukemia cells in preclinical models.
It is commonly applied in studies aimed at understanding the molecular mechanisms of MLL-fusion-driven leukemogenesis. Researchers use CPI-169 to evaluate the therapeutic potential of targeting the menin-MLL interface, making it a valuable tool compound in oncology drug discovery. Its high selectivity and cellular activity support its use in in vitro and in vivo experiments to assess anti-leukemic effects, often in combination with other targeted agents.
Due to its ability to induce differentiation and apoptosis in leukemia cell lines, CPI-169 is also used to explore epigenetic regulation in cancer. While still in the investigational stage, it serves as a lead candidate for the development of novel therapies for acute leukemias with MLL rearrangements.
Sizes / Availability / Pricing:
| Size | Availability | Price | Quantity |
|---|---|---|---|
| 1ml | 10-20 days | ฿10,760.00 |
+
-
|
CPI-169
CPI-169 is primarily used in research settings as a potent and selective inhibitor of the menin-MLL (mixed lineage leukemia) protein-protein interaction. This interaction plays a critical role in the development and progression of certain types of leukemia, particularly MLL-rearranged (MLL-r) leukemias. By disrupting this interaction, CPI-169 has shown promise in suppressing the growth of leukemia cells in preclinical models.
It is commonly applied in studies aimed at understanding the molecular mechanisms of MLL-fusion-driven leukemogenesis. Researchers use CPI-169 to evaluate the therapeutic potential of targeting the menin-MLL interface, making it a valuable tool compound in oncology drug discovery. Its high selectivity and cellular activity support its use in in vitro and in vivo experiments to assess anti-leukemic effects, often in combination with other targeted agents.
Due to its ability to induce differentiation and apoptosis in leukemia cell lines, CPI-169 is also used to explore epigenetic regulation in cancer. While still in the investigational stage, it serves as a lead candidate for the development of novel therapies for acute leukemias with MLL rearrangements.
| Mechanism | - |
| Appearance | - |
| Longevity | - |
| Strength | - |
| Storage | - |
| Shelf Life | - |
| Allergen(s) | - |
| Dosage (Range) | - |
| Recommended Dosage | - |
| Dosage (Per Day) | - |
| Recommended Dosage (Per Day) | - |
| Mix Method | - |
| Heat Resistance | - |
| Stable in pH range | - |
| Solubility | - |
| Product Types | - |
| INCI | - |
Purchase History for
Loading purchase history...
Cart
No products
Subtotal:
฿0.00
฿0.00
Total :